Back to List View Graph View

PD-1/PD-L1 blockade

PD-1/PD-L1 blockade refers to therapeutic inhibition of the Programmed cell death 1 (PD-1) receptor and its ligand CD274 molecule, an immune checkpoint axis that normally restrains T-cell activation.

Where the papers sit

18 papers from the last 6 months study PD-1/PD-L1 blockade directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 4 observational · 2 human data · 11 preclinical · 1 unclassified

Themes 4 themes

  • Predicting Immunotherapy Response

    Immune checkpoint treatment is moving toward biomarker-guided combinations and risk stratification across solid tumors. Response depth predicts progression risk, while Tregs, FN1+ macrophages, and lactate-linked HMGB1/HIF-1α signaling recur as mechanisms of immune escape or resistance. Peripheral T-cell subsets and blood-based kinase activity profiling are being developed to predict benefit in cervical cancer and NSCLC. Axitinib plus survivin vaccination illustrates efforts to make PD-1 therapy durable in renal carcinoma.

    7 papers · 38.9%

  • PD-1 Signaling Beyond Cancer

    PD-1/PD-L1 modulation is being extended from cancer to sepsis, cardiac homeostasis, and invasive mold infections. Moxibustion plus nivolumab improved immunosuppression in septic mice, potentially through CD44/JAK2/STAT3 signaling. Myeloid PD-1/PD-L1 signaling appears important for adult heart maintenance, while IFN-γ is being explored alongside anti-PD-1 in infection. Cancer studies point to β-catenin-driven ferroptosis resistance as another route to PD-L1-mediated immune evasion.

    5 papers · 27.8%

  • PD-L1 Biology and Monitoring

    PD-L1 biology is being connected to tumor immunity, immune regulation, and treatment monitoring across multiple cancers. Studies include PD-1/PD-L1 signaling in multiple myeloma and strategies for delivering PD-L1-targeting plasmids with copper complexes for chemoimmunotherapy. Regulatory T-cell dysfunction is emerging as a potential consequence of checkpoint inhibition rather than only a barrier to it. CRISPR/Cas12a detection of exosome RNA offers a route to monitor tumor progression, but therapeutic and monitoring approaches remain exploratory.

    4 papers · 22.2%

  • Tumor Microenvironment Reprogramming

    Local remodeling of immunosuppressive tumor microenvironments is being used to strengthen PD-1 blockade. TAM-targeting nano-immunotherapy seeks to reverse macrophage-driven suppression through biodegradable polymers, biomimetic vesicles, and flexible carriers. Intratumoral bicarbonate is being tested as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma. The evidence remains primarily preclinical, with the key question being whether local reprogramming improves antitumor immunity in vivo.

    2 papers · 11.1%

Papers

The 18 papers from the last 6 months that study PD-1/PD-L1 blockade directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Predicting Immunotherapy Response (7)
  1. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology · 26 Jun 2026 PMID 42361199
  2. Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma. Oncoimmunology · 25 Jun 2026 PMID 42343214
  3. Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342406
  4. EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814
  5. Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer. Human vaccines & immunotherapeutics · 23 Jun 2026 PMID 42334275
  6. Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284973
  7. FN1+ macrophages fuel aggressive sarcomatoid differentiation and immunotherapy refractory outcome in clear cell renal cell carcinoma. Oncogene · 5 Jun 2026 PMID 42249083
PD-1 Signaling Beyond Cancer (5)
  1. Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
  2. Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
  3. Myeloid-derived immunosuppressive PD-1/PD-L1 signaling is essential to maintain adult heart homeostasis. American journal of physiology. Heart and circulatory physiology · 1 Jun 2026 PMID 42223114
  4. Druggable β-catenin palmitoyl-switch coordinates immune evasion via immunogenic ferroptosis resistance and PD-L1-mediated immunosuppression. Cell reports. Medicine · 28 May 2026 PMID 42208545
  5. Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections. mBio · 22 May 2026 PMID 42171361
PD-L1 Biology and Monitoring (4)
  1. Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
  2. Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma. Journal of the Egyptian National Cancer Institute · 17 Jun 2026 PMID 42307688
  3. Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
  4. An Exosome RNA In Situ Detection Platform Based on a Regulated CRISPR/Cas12a Activity System and Its Application in Tumor Progression Monitoring and Therapeutic Efficacy Evaluation. Analytical chemistry · 3 Jun 2026 PMID 42231680
Tumor Microenvironment Reprogramming (2)
  1. Nano-Immunotherapy Targeting TAMs: Precisely Regulating TAMs to Reverse Immunosuppressive TME. International journal of nanomedicine · 23 Jun 2026 PMID 42333283
  2. Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma. Oncogene · 4 Jun 2026 PMID 42243329

By study type

Observational studies and case reports (4)
  1. Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study. Journal for immunotherapy of cancer · 24 Jun 2026 PMID 42342406
  2. Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer. Human vaccines & immunotherapeutics · 23 Jun 2026 PMID 42334275
  3. Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma. Journal of the Egyptian National Cancer Institute · 17 Jun 2026 PMID 42307688
  4. Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC. European journal of cancer (Oxford, England : 1990) · 12 Jun 2026 PMID 42284973
Human data, design not indexed (2)
  1. Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
  2. Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections. mBio · 22 May 2026 PMID 42171361
Preclinical: animal, cell and lab studies (11)
  1. Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
  2. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Science immunology · 26 Jun 2026 PMID 42361199
  3. Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma. Oncoimmunology · 25 Jun 2026 PMID 42343214
  4. Nano-Immunotherapy Targeting TAMs: Precisely Regulating TAMs to Reverse Immunosuppressive TME. International journal of nanomedicine · 23 Jun 2026 PMID 42333283
  5. Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway. Immunologic research · 17 Jun 2026 PMID 42307810
  6. FN1+ macrophages fuel aggressive sarcomatoid differentiation and immunotherapy refractory outcome in clear cell renal cell carcinoma. Oncogene · 5 Jun 2026 PMID 42249083
  7. Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma. Oncogene · 4 Jun 2026 PMID 42243329
  8. Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
  9. An Exosome RNA In Situ Detection Platform Based on a Regulated CRISPR/Cas12a Activity System and Its Application in Tumor Progression Monitoring and Therapeutic Efficacy Evaluation. Analytical chemistry · 3 Jun 2026 PMID 42231680
  10. Myeloid-derived immunosuppressive PD-1/PD-L1 signaling is essential to maintain adult heart homeostasis. American journal of physiology. Heart and circulatory physiology · 1 Jun 2026 PMID 42223114
  11. Druggable β-catenin palmitoyl-switch coordinates immune evasion via immunogenic ferroptosis resistance and PD-L1-mediated immunosuppression. Cell reports. Medicine · 28 May 2026 PMID 42208545
Unclassified: not yet indexed with MeSH (1)
  1. EFHD2 drives lactate-mediated DNA damage repair and immunosuppression via HMGB1 and HIF-1α to confer radioresistance in colorectal cancer. Cell death & disease · 23 Jun 2026 PMID 42336814